STOCK TITAN

Hologic Inc - HOLX STOCK NEWS

Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.

Hologic Inc. (NASDAQ: HOLX) is a leading global healthcare company dedicated to the science of sure. Headquartered in Bedford, Massachusetts, Hologic specializes in developing, marketing, and servicing some of the most innovative and accurate diagnostic imaging systems and surgical products available today. The company's core business focuses on meeting the healthcare needs of women, operating through five primary segments: diagnostics, breast health, surgical, and skeletal health.

Diagnostics, which accounts for 60% of total sales, has seen a significant boost due to the pandemic, underscoring the company's strategic pivot toward commercial diagnostics following the acquisition of Gen-Probe. This segment includes a wide range of tests and instruments essential for early disease detection and management.

Breast Health, traditionally a cornerstone of Hologic’s business, contributes 14% to total sales. Though this segment was initially suppressed by the pandemic, it remains vital for innovations in mammography and breast surgery. Hologic's Surgical segment, representing 11% of sales, offers advanced products that enhance surgical outcomes and patient safety. The Skeletal Health segment, although smaller at 1% of total sales, provides critical tools for assessing bone health.

Hologic’s reach is vast, with the United States accounting for 69% of its revenue, followed by Europe at 20%, Asia at 8%, and other international markets making up the remaining 3%. The company's diverse, dedicated, and creative team is committed to not only advancing medical science but also providing greater confidence and peace of mind in diagnosis, enabling healthier lives worldwide.

Stay updated with the latest from Hologic by connecting on Hologic.com, Facebook, and Twitter.

Rhea-AI Summary

Hologic (Nasdaq: HOLX) announced that it will release its financial results for the third quarter of fiscal 2024 on July 29, 2024, after the market closes.

Management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. To participate, dial (888) 394-8218 in the U.S. and Canada, or +1 (773) 305-6853 internationally, using access code 5372869. Alternatively, participants can join the webcast on Hologic's investor relations website.

A live and recorded webcast replay will be available on the website for 30 days, starting about two hours after the call concludes.

Hologic focuses on medical technologies that improve women's health and well-being through early detection and treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
-
Rhea-AI Summary

Hologic (Nasdaq: HOLX) has announced its participation in two upcoming investor conferences. The company will present at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on May 29th at 10 a.m. CT. Additionally, Hologic will present at the William Blair 44th Annual Growth Stock Conference in Chicago, Illinois on June 4th at 8:40 a.m. CT. Both presentations will be webcast live and available for 30 days on the company’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences
-
Rhea-AI Summary

Hologic, Inc. (Nasdaq: HOLX) announced Q2 fiscal 2024 results, with revenue of $1,017.8M, GAAP EPS $0.72, Non-GAAP EPS $1.03, exceeding guidance. Total company organic revenue growth was 4.9% in constant currency. The company raised full-year revenue midpoint and EPS guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
Rhea-AI Summary

Hologic, Inc. (Nasdaq: HOLX) announced the acquisition of Endomagnetics for $310 million, enhancing their breast surgery portfolio with innovative technologies. The deal is expected to expand options for breast cancer procedures, increase global access to advanced solutions, and improve patient care. Endomag's revenue in 2023 was approximately $35 million. The acquisition will be slightly dilutive to Hologic's non-GAAP earnings per share in 2024, break even in 2025, and accretive thereafter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
-
Rhea-AI Summary
Bayer and Hologic Collaborate on Contrast-Enhanced Mammography Solution at Society of Breast Imaging Symposium, Aiming to Streamline Access and Education for Radiologists and Imaging Facilities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
-
Rhea-AI Summary
Hologic, Inc. (HOLX) will release its Q2 fiscal 2024 results on May 2, with a conference call at 4:30 p.m. ET. Interested parties can join via phone or webcast. Replay will be available on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
Rhea-AI Summary
Hologic, Inc. and Biotheranostics, Inc. announce study results showing 40% of patients with early-stage HR+ breast cancer had treatment recommendations changed based on the Breast Cancer Index test. The test helps identify women who may benefit from extended anti-estrogen therapy, avoiding both overtreatment and undertreatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
Rhea-AI Summary
Hologic, Inc. (Nasdaq: HOLX) presents new research in artificial intelligence (AI) at the annual European Congress of Radiology, showcasing the potential of deep-learning solutions in breast cancer detection. Dr. Sarah M. Friedewald will discuss the impact of Hologic's Genius AI® Detection solution on workflow efficiency and patient care. The company also highlights the superiority of its AI algorithm over traditional CAD algorithms, emphasizing innovation and collaboration with Bayer on contrast-enhanced mammography.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
AI
-
Rhea-AI Summary
Hologic, Inc. (HOLX) to present at Raymond James' Institutional Investors Conference and Needham Virtual Healthcare Conference. Webcasts available for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
conferences
Rhea-AI Summary
Hologic, Inc. has received FDA clearance for its Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm, the first FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
none

FAQ

What is the current stock price of Hologic (HOLX)?

The current stock price of Hologic (HOLX) is $70.7 as of January 23, 2025.

What is the market cap of Hologic (HOLX)?

The market cap of Hologic (HOLX) is approximately 15.9B.

What does Hologic Inc. specialize in?

Hologic Inc. specializes in developing, marketing, and servicing innovative and accurate diagnostic imaging systems and surgical products, with a focus on women's healthcare.

Where is Hologic Inc. headquartered?

Hologic Inc. is headquartered in Bedford, Massachusetts.

What are the main segments of Hologic’s business?

Hologic operates in five main segments: diagnostics, breast health, surgical, and skeletal health.

Which segment contributes the most to Hologic's revenue?

The diagnostics segment contributes the most, accounting for 60% of Hologic's total sales.

How has the pandemic affected Hologic’s business segments?

The pandemic boosted the diagnostics segment but initially suppressed the breast health segment.

What percentage of Hologic’s revenue comes from the United States?

69% of Hologic’s revenue comes from the United States.

How did the acquisition of Gen-Probe impact Hologic?

The acquisition of Gen-Probe shifted Hologic’s focus more towards commercial diagnostics.

How can I stay updated with Hologic's latest news?

You can stay updated by visiting Hologic's website, or following them on Facebook and Twitter.

What is Hologic’s approach to healthcare?

Hologic is dedicated to the science of sure, providing greater confidence and peace of mind in medical diagnosis to enable healthier lives.

What percentage of Hologic’s revenue comes from international markets?

Approximately 31% of Hologic’s revenue comes from international markets, including Europe, Asia, and other regions.
Hologic Inc

Nasdaq:HOLX

HOLX Rankings

HOLX Stock Data

15.93B
223.83M
0.8%
105.31%
2.71%
Medical Instruments & Supplies
X-ray Apparatus & Tubes & Related Irradiation Apparatus
Link
United States of America
MARLBOROUGH